CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $728,000 | -91.6% | 25,888 | -83.9% | 0.00% | -90.9% |
| Q3 2021 | $8,707,000 | -28.5% | 161,276 | -55.7% | 0.01% | -26.7% |
| Q2 2021 | $12,173,000 | +9.1% | 364,027 | -32.8% | 0.02% | +7.1% |
| Q1 2021 | $11,153,000 | -39.3% | 541,427 | -48.4% | 0.01% | -30.0% |
| Q4 2020 | $18,375,000 | -28.7% | 1,048,827 | -39.6% | 0.02% | -23.1% |
| Q3 2020 | $25,755,000 | +21.0% | 1,736,675 | +6.1% | 0.03% | +44.4% |
| Q2 2020 | $21,283,000 | +995.4% | 1,637,175 | +39.9% | 0.02% | +800.0% |
| Q1 2020 | $1,943,000 | -21.9% | 1,170,187 | +4.9% | 0.00% | 0.0% |
| Q4 2019 | $2,487,000 | +13.8% | 1,115,368 | +8.7% | 0.00% | 0.0% |
| Q3 2019 | $2,186,000 | -10.6% | 1,026,285 | +12.5% | 0.00% | 0.0% |
| Q2 2019 | $2,445,000 | -8.8% | 912,285 | +67.4% | 0.00% | 0.0% |
| Q1 2019 | $2,682,000 | – | 545,106 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,132,259 | $30,526,000 | 7.80% |
| Ghost Tree Capital, LLC | 400,000 | $10,784,000 | 5.62% |
| Octagon Capital Advisors LP | 761,398 | $20,527,000 | 5.48% |
| VR Adviser, LLC | 865,116 | $23,324,000 | 4.59% |
| ACUTA CAPITAL PARTNERS, LLC | 267,195 | $7,204,000 | 4.01% |
| COMMODORE CAPITAL LP | 538,812 | $14,526,000 | 3.07% |
| Ikarian Capital, LLC | 616,700 | $16,628,000 | 3.03% |
| TSP Capital Management Group, LLC | 266,545 | $7,186,000 | 2.83% |
| Ikarian Capital, LLC | 537,958 | $14,504,000 | 2.64% |
| Ikarian Capital, LLC | 506,500 | $13,656,000 | 2.49% |